ATYPICAL COURSE OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CLINICAL CASE)

DOI:

https://doi.org/10.54890/.v5i5.1242

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a potentially curable disease, the course and outcome of which largely depend on the timing of the start of pathogenetic therapy, so early diagnosis is important. In turn, untimely treatment of CVDP is accompanied by secondary axonopathy, the consequence of which is severe residual neurological deficit, deterioration of working capacity and quality of life of patients. The aim of the article was to describe a clinical case of atypical course of chronic inflammatory demyelinating polyneuropathy in a patient with comorbid pathology. Clinical data and the results of laboratory and instrumental methods of investigation were analyzed. As a result of successful treatment of the patient with intravenous immunoglobulin, significant improvement of the condition and restoration of lost motor functions were observed. The presented clinical case is an example of a long and complicated diagnostic search on the way of making the correct final diagnosis. The article may be useful for both young and experienced neurologists and related specialists, such as intensive care doctors, rheumatologists, rheumatologist, family doctors, cardiologists, therapists, and others.

Keywords:

Chronic inflammatory demyelinating polyneuropathy (CIDP), autoimmune disease, atypical course, and comorbid pathology, immunoglobulin, motor functions.

Author Biographies

E.M. Mamytova, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of Neurology and Clinical Genetics named after acad. A.M. Murzaliev

A.K. Kazybekov, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of Neurology and Clinical Genetics named after acad. A.M. Murzaliev

References

1. Brun S, de Sèze J, Muller S. CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention. Immuno. 2022;2(1):118-131. https://doi.org/10.3390/immuno2010009

2. Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2019;52(3-4):161-172. https://doi.org/10.1159/000494291

3. Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve. 2009;39(4):432-438. https://doi.org/10.1002/mus.21206

4. Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019;18(8):784-794. https://doi.org/10.1016/S1474-4422(19)30144-9

5. Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86(9):973-985. https://doi.org/10.1136/jnnp-2014-309697

6. Кутепов Д.Е., Литвинов Н.И. Синдром Гийена-Барре. Казанский медицинский журнал. 2015;96(6):1027-1033. https://doi.org/10.17750/KMJ2015-1027

7. Гапешин Р.Ф., Баранцевич Е.Р., Яковлев А.А. Патогенез, особенности клинической картины и лабораторной диагностики хронической воспалительной демиелинизирующей полинейропатии. Ученые записи СПбГМУ им. акад. И.П. Павлова. 2018;25(3)614-24.

8. Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015;85(6):498-504. https://doi.org/10.1212/WNL.0000000000001833

Published

2024-02-26

How to Cite

Мамытова, Э., А. Казыбеков, Г. . Биялиева, and С. Омурбеков. “ATYPICAL COURSE OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CLINICAL CASE) ”. Euroasian Health Journal, vol. 5, no. 5, Feb. 2024, pp. 41-46, doi:10.54890/.v5i5.1242.

Issue

Section

INTERNAL MEDICINE